

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA PIONEER PHARMA HOLDINGS LIMITED

中国先锋医药控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01345)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 22 DECEMBER 2016

Reference is made to the circular (the “**Circular**”) and the notice of extraordinary general meeting (the “**EGM Notice**”) of China Pioneer Pharma Holdings Limited (the “**Company**”) both dated 6 December 2016. Capitalised terms used in this announcement shall have the same meanings as defined in the Circular unless the context otherwise requires.

At the EGM held on 22 December 2016, voting on the proposed resolution as set out in the EGM Notice was taken by poll.

As at the date of the EGM, the total number of Shares in issue was 1,333,334,000. As disclosed in the Circular, Mr. Li and his associates holding an aggregate of 932,879,000 Shares will abstain, and at the EGM, Mr. Li and his associates abstained from voting on the resolution proposed at the EGM. Further, the trustee of the China Pioneer Pharma Share Award Scheme adopted by the Company on 10 April 2015 holding 39,113,000 Shares also abstained from voting on the resolution proposed at the EGM. Accordingly, there were in aggregate 361,342,000 Shares entitling the holders to attend the EGM and vote for or against the resolution. No Shareholder was required to attend and vote only against the resolution at the EGM. Save as disclosed above, there were no restrictions on any Shareholders casting vote on the proposed resolution at the EGM.

The Company's Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking. The poll results in respect of the resolution proposed at the EGM were as follows:

ORDINARY RESOLUTION	Number of votes cast and approximate percentage of total number of votes cast	
	For	Against
THAT the execution and delivery of and the performance of the obligations under the share purchase agreement dated 17 October 2016, as amended and supplemented by the supplemental agreement dated 2 December 2016 (the “Supplemental Agreement”), entered into between the Pioneer Pharma (Hong Kong) Co., Limited (as seller) and Mr. Li Xinzhou (as purchaser) in relation to the sale and purchase (the “Disposal”) of the one ordinary share of SG\$1 in Pioneer Pharma (Singapore) Pte. Ltd. (the “Agreement”) by the Company and the transactions contemplated thereunder be and are hereby approved, ratified and confirmed; and any one director of the Company be and is hereby authorised to sign, agree, ratify, perfect, execute or deliver (including under seal where applicable) such documents and to do or authorise doing all such acts and things incidental to the Agreement and the Supplemental Agreement and the transactions contemplated thereunder as he may in his absolute discretion consider necessary, desirable or expedient and in the best interest of the Company in connection with the implementation of, giving effect to or completion of the Disposal and the transactions contemplated thereunder.	84,982,050 95.68%	3,840,000 4.32%

As more than 50% of votes were cast in favour of the resolution, the resolution was duly passed as an ordinary resolution of the Company.

By order of the Board
China Pioneer Pharma Holdings Limited
Li Xinzhou
Chairman

Hong Kong, 22 December 2016

As at the date of this announcement, the Directors are Mr. LI Xinzhou, Mr. WANG Yinpeng and Mr. ZHU Mengjun as executive Directors, Mr. WU Mijia as non-executive Director and Mr. XU Zhonghai, Mr. LAI Chanshu and Mr. WONG Chi Hung, Stanley as independent non-executive Directors.